Compare Intel Corp (INTC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Pfizer Inc — how do they compare? Intel Corp trades at $108.84 (market cap $566.04B), while Pfizer Inc trades at $27.83 (market cap $158.56B). The key difference: Intel Corp is far larger — about 3.6× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Pfizer Inc for 158 Days on average.
| INTC | PFE | |
|---|---|---|
Market Cap | $566.04B | $158.56B |
Volume | 118,475,837 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $140.94 | $29.02 |
52-Week Low | $33.62 | $23.67 |
Typical Hold Time | 116 Days | 158 Days |
Enterprise Value | $586.85B | $210.06B |
Dividend Yield | 2.24% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $113.12, up 0.55% today, with a bullish technical signal and recent earnings beats. The stock has surged over 220% in 2026, driven by AI momentum and foundry growth, though fundamentals show negative net income margins and elevated valuations. Cash flow improved in 2025, but revenue remains below 2022 peaks amid intense competition.
Outlook hinges on foundry turnaround execution; upside exists if Intel captures external customers for advanced nodes, but high debt and margin pressures pose risks. Analyst consensus is cautious with a $111.72 target, slightly below current price, reflecting skepticism on sustainability despite recent gains.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
